Sansure Biotech (SHSE:688289) Beneish M-Score: -2.53 (As of Jun. 28, 2026)


SHSE:688289 Sansure Biotech Inc SHSE:688289
67 GF Score
Price ¥14.12
GF Value ¥20.52
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sansure Biotech Beneish M-Score?

Sansure Biotech SHSE:688289 +1.80% 67 Beneish M-Score is -2.53 as of Jun. 28, 2026. GuruFocus rates SHSE:688289 with a GF Score™ of 67/100 and a GF Value™ of ¥20.52 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Sansure Biotech ranks worse than 55.09% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.53 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sansure Biotech's Beneish M-Score or its related term are showing as below:

SHSE:688289' s Beneish M-Score Range Over the Past 10 Years
Min: -2.75   Med: -2.16   Max: 7.38
Current: -2.53

During the past 9 years, the highest Beneish M-Score of Sansure Biotech was 7.38. The lowest was -2.75. And the median was -2.16.


Sansure Biotech Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sansure Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sansure Biotech Beneish M-Score Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -0.85 -2.41 -0.93 -2.56 -2.36

Sansure Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.41 -2.33 -2.26 -2.36 -2.53

SHSE:688289 vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Sansure Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sansure Biotech Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sansure Biotech's Beneish M-Score falls into.


SHSE:688289
67GF Score
Sansure Biotech Inc SHSE:688289
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sansure Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sansure Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8658+0.528 * 1.0254+0.404 * 1.1867+0.892 * 1.0394+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9909+4.679 * -0.006232-0.327 * 1.0577
=-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥712 Mil.
Revenue was 437.346 + 397.394 + 375.519 + 393.132 = ¥1,603 Mil.
Gross Profit was 320.637 + 336.131 + 271.368 + 271.792 = ¥1,200 Mil.
Total Current Assets was ¥5,161 Mil.
Total Assets was ¥9,607 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,323 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥376 Mil.
Total Current Liabilities was ¥1,211 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,017 Mil.
Net Income was 49.739 + 7.616 + 28.602 + 70.984 = ¥157 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -0.964 + 268.441 + 58.367 + -109.03 = ¥217 Mil.
Total Receivables was ¥791 Mil.
Revenue was 475.488 + 425.481 + 315.623 + 326.011 = ¥1,543 Mil.
Gross Profit was 364.762 + 335.74 + 246.304 + 236.92 = ¥1,184 Mil.
Total Current Assets was ¥5,776 Mil.
Total Assets was ¥9,684 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,256 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥365 Mil.
Total Current Liabilities was ¥1,301 Mil.
Long-Term Debt & Capital Lease Obligation was ¥822 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(712.213 / 1603.391) / (791.404 / 1542.603)
=0.444192 / 0.513032
=0.8658

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1183.726 / 1542.603) / (1199.928 / 1603.391)
=0.767356 / 0.748369
=1.0254

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5160.631 + 1323.432) / 9606.771) / (1 - (5776.19 + 1255.561) / 9684.305)
=0.325053 / 0.273902
=1.1867

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1603.391 / 1542.603
=1.0394

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1255.561)) / (0 / (0 + 1323.432))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(376.388 / 1603.391) / (365.458 / 1542.603)
=0.234745 / 0.23691
=0.9909

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1016.792 + 1210.639) / 9606.771) / ((821.603 + 1301.244) / 9684.305)
=0.231861 / 0.219205
=1.0577

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(156.941 - 0 - 216.814) / 9606.771
=-0.006232

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sansure Biotech has a M-score of -2.53 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.53 mean?
Sansure Biotech (SHSE:688289) has a Beneish M-Score of -2.53 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sansure Biotech and its competitors. According to the industry distribution chart, Sansure Biotech ranks #422 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 55.1%.
Is Sansure Biotech's Beneish M-Score too high?
Sansure Biotech's current Beneish M-Score is -2.53. Based on the distribution chart, Sansure Biotech ranks #422 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sansure Biotech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sansure Biotech ranks #422 out of 766 companies for Beneish M-Score. This places Sansure Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sansure Biotech and its competitors. Sansure Biotech's current Beneish M-Score is -2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.52, compared to a current price of ¥14.12 — trading 31.2% below its estimated fair value. The current Beneish M-Score is -2.53. Sansure Biotech's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Beneish M-Score is -2.53 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sansure Biotech (SHSE:688289) Overvalued in 2026?

Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued. The current stock price of ¥14.12 is trading 31.2% below its estimated GF Value™ of ¥20.52. GuruFocus considers Sansure Biotech to be Possible Value Trap.

Key valuation signals for SHSE:688289:

  • Beneish M-Score: -2.53
  • GF Value™: ¥20.52 vs. price of ¥14.12 (31.2% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sansure Biotech Business Description

Address No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in the Research, development, production, and sales of diagnostic reagents and instruments.
67GF Score

Get the complete analysis for SHSE:688289

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.12
Price
¥20.52
GF Value